Science Explorer Back to mapMap
Discussion
Company · Nottingham · United Kingdom

Astrimmune (United Kingdom)

astrimmune.comROR OpenAlex
Research works
9
▼ 87% vs 2018-21
Citations
147
16.7 per fractional work
Top-10% rate
28.1%
all institutions 10.0%
Open access
24%
world 40%
International
35%
world 18%
Astrimmune (United Kingdom)

Not ranked overall: Astrimmune (United Kingdom) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Astrimmune (United Kingdom) work in?

In all years, 64% of research at Astrimmune (United Kingdom) is in Health Sciences, 30% in Life Sciences. Its largest fields are Medicine (64%), Biochemistry, Genetics and Molecular Biology (23%), Immunology and Microbiology (5%). It does 1.7× the world's share of Health Sciences.

Health Sciences: 6 fractional works · 63.8% of its workMedicine: 6 fractional works · 63.8% of its workRadiology, Nuclear Medicine and Imaging: 3 fractional works · 29.9% of its workPulmonary and Respiratory Medicine: 2 fractional works · 20.7% of its workOncology: 1 fractional works · 6.5% of its workHepatology: 0 fractional works · 2.9% of its workNeurology: 0 fractional works · 1.9% of its workSurgery: 0 fractional works · 0.9% of its workEpidemiology: 0 fractional works · 0.5% of its workInfectious Diseases: 0 fractional works · 0.5% of its workLife Sciences: 3 fractional works · 29.7% of its workBiochemistry, Genetics and Molecular Biology: 2 fractional works · 23.1% of its workMolecular Biology: 1 fractional works · 7.8% of its workGenetics: 1 fractional works · 5.8% of its workBiotechnology: 0 fractional works · 5.7% of its workBiophysics: 0 fractional works · 3.7% of its workImmunology and Microbiology: 0 fractional works · 5.4% of its workImmunology: 0 fractional works · 4.8% of its workVirology: 0 fractional works · 0.8% of its workAgricultural and Biological Sciences: 0 fractional works · 0.8% of its workPlant Science: 0 fractional works · 0.8% of its workNeuroscience: 0 fractional works · 0.3% of its workCellular and Molecular Neuroscience: 0 fractional works · 0.3% of its workPhysical Sciences: 1 fractional works · 6.5% of its workEngineering: 0 fractional works · 3.7% of its workBiomedical Engineering: 0 fractional works · 3.7% of its workComputer Science: 0 fractional works · 1.9% of its workArtificial Intelligence: 0 fractional works · 1.9% of its workEnvironmental Science: 0 fractional works · 0.8% of its workEcology: 0 fractional works · 0.8% of its workALL ITS WORKAstrimmune(United Kingdom)9fractional works, all years
Life Sciences30%Physical Sciences6%Health Sciences64%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 3 domains and 8 fields, with their numbers
    1. Medicine663.8%
    1. Biochemistry, Genetics and Molecular Biology223.1%
    2. Immunology and Microbiology05.4%
    3. Agricultural and Biological Sciences00.8%
    4. Neuroscience00.3%
    1. Engineering03.7%
    2. Computer Science01.9%
    3. Environmental Science00.8%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

What are the most cited papers from Astrimmune (United Kingdom)?

The most cited paper from Astrimmune (United Kingdom) is "Audit of the autoantibody test, EarlyCDT®-Lung, in 1600 patients: An evaluation of its performance in routine clinical practice" (James R. Jett, Laura J. Peek, Lynn Fredericks et al., 2013), with 244 citations. Next come "Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule-Based Risk Models for Detection of Lung Cancer" (104) and "Cost-effectiveness of an autoantibody test (EarlyCDT-Lung) as an aid to early diagnosis of lung cancer in patients with incidentally detected pulmonary nodules" (41).

Most cited papers
#PaperReleasedCitations
1 Audit of the autoantibody test, EarlyCDT®-Lung, in 1600 patients: An evaluation of its performance in routine clinical practice James R. Jett, Laura J. Peek, Lynn Fredericks et al. · Lung Cancer Open access 22 Oct 2013 244
2 Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule-Based Risk Models for Detection of Lung Cancer Pierre Pascal Massion, Graham F. Healey, Laura J. Peek et al. · Journal of Thoracic Oncology Open access 12 Sep 2016 104
3 Cost-effectiveness of an autoantibody test (EarlyCDT-Lung) as an aid to early diagnosis of lung cancer in patients with incidentally detected pulmonary nodules John Edelsberg, Derek A. Weycker, Mark Atwood et al. · PLoS ONE Open access 22 May 2018 41
4 A Structural Model for the Generation of Continuous Curvature on the Surface of a Retroviral Capsid Graham D. Bailey, Jaekyung Hyun, ALOK KUMAR MITRA et al. · Journal of Molecular Biology 30 Jan 2012 36
5 Use of autoantibodies in breast cancer screening and diagnosis Sarah J. Storr, Jayeta Chakrabarti, Anthony C. Barnes et al. · Expert Review of Anticancer Therapy Open access Aug 2006 32
All 18 most cited papers, with filters and sorting

Which research topics does Astrimmune (United Kingdom) publish most on?

By volume in 2022-now: Bladder and Urothelial Cancer Treatments, Cancer Immunotherapy and Biomarkers, Monoclonal and Polyclonal Antibodies Research and COVID-19 Clinical Research Studies.

Bladder and Urothelial C…0Bladder and Urothelial Cancer Treatments: 0 fractional worksCancer Immunotherapy and…0Cancer Immunotherapy and Biomarkers: 0 fractional worksMonoclonal and Polyclona…0Monoclonal and Polyclonal Antibodies Research: 0 fractional works
SurgeryOncologyRadiology, Nuclear Medicine and Imaging

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Bladder and Urothelial Cancer Treatments Surgery 0 works
  2. 2 Cancer Immunotherapy and Biomarkers Oncology 0 works
  3. 3 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 0 works
  4. 4 COVID-19 Clinical Research Studies Infectious Diseases 0 works
  5. 5 Long-Term Effects of COVID-19 Neurology 0 works
  6. 6 Pharmacological Receptor Mechanisms and Effects Molecular Biology 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available23.5%not open76.5%

World: 40% of research is openly available.

with international co-authors35.2%domestic only64.8%

World: 18% is written across borders.

How has Astrimmune (United Kingdom)'s research output changed?

Output in 2022-2025 was 87% lower than in 2018-2021.

20002005201020152020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Astrimmune (United Kingdom) as a percentage of every work published that year, 0.0000048% in 2022.

0.000020%0.000040%0.000060%Astrimmune (United Kingdom)0.0000013% in 2024200020102020

Fractional works of Astrimmune (United Kingdom) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Nottingham

All research institutions in Nottingham

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Astrimmune (United Kingdom). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.